Status:
UNKNOWN
Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients
Lead Sponsor:
Tehran University of Medical Sciences
Conditions:
Hematopoietic Stem Cell Transplantation (HSCT)
COVID-19 Vaccines
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
COVID-19 vaccinations are predicted to be a huge success in pandemic control. However, the majority of the studies were conducted on healthy individuals, and the efficiency of COVID-19 vaccination in ...
Detailed Description
From the start of the study until the sample size of 100 patients is attained, all consecutive adult patients who are candidates for Allo-SCT at HORCSCT, sign a research project consent to administer ...
Eligibility Criteria
Inclusion
- Age ≥ 18 years, successfully engraftment with full donor chimerism, absence of grade 3,4 acute GvHD or severe extensive chronic GvHD, no receive more than 0.5 mg/kg prednisolone, and no positive RT-PCR test for COVID-19 following HSCT
Exclusion
- Patients who are not candidates for the COVID-19 vaccine after transplantation due to severe complications.
- Patients who do not consent to vaccination after transplantation
Key Trial Info
Start Date :
November 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05185817
Start Date
November 1 2021
End Date
July 1 2023
Last Update
May 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematology, Oncology, and Stem Cell Transplantation Research Center of shariaty Hospital
Tehran, Iran, 1417713135